2024
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
2023
Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response rate